Our client:

ASLAN Pharmaceuticals is a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. It is dual listed on the Taipei and NASDAQ exchanges.


The challenge:

The RSA Group was appointed to find a new non-executive director to join ASLAN Pharmaceutical’s board. The Company was planning a funding round and was looking to shift the investment focus towards the US. Aslan therefore needed an individual with oncology experience who would have credibility with US investors and who would need to be able to run an audit committee working to US GAAP. Aslan is headquartered in Singapore, so the challenging time difference meant the search had to be focused on the US West Coast, significantly narrowing our search.



How our approach made a difference:

We began by carrying out a geographically focused search, with consultants working across Asia, UK and one of the US offices. By understanding the client’s needs and thanks to the careful due diligence of the consultants, an appointment was made just 5 weeks after we were retained. The appointee had extensive oncology biotech experience, as CFO for a large therapeutics company and audit committee chair of an oncology company. As a result, ASLAN Pharmaceuticals gained immediate expertise into scaling a US quoted oncology business and increased its credibility with investors across US and Asia.


Share this: